<DOC>
	<DOCNO>NCT00479752</DOCNO>
	<brief_summary>To assess efficacy FOLFOX4 combination cetuximab , weekly FOLFOX4 combination cetuximab , biweekly .</brief_summary>
	<brief_title>Safety Efficacy Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This multicenter randomize phase II study enroll approximately 150 patient metastatic Colorectal Cancer . Patients randomize Arm A ( FOLFOX4 combination weekly Cetuximab ) Arm B ( FOLFOX4 combination biweekly Cetuximab ) . Both efficacy safety data collect . The investigator assess response treatment every 8 week base image . Following permanent treatment cessation , patient followed-up survival .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent Male female ≥ 18 year age Diagnosis histologically confirm adenocarcinoma colon rectum Metastatic colorectal carcinoma suitable curativeintent resection Availability tumor sample ( able willing provide tumor sample ) EGFR assessment Presence least one lesion measurable unidimensionally CT scan MRI . ( Target lesion ( ) must lie within irradiated area ) Karnofsky performance status &gt; 80 study entry Leucocytes ≥ 3.0 x 10 9/L neutrophil ≥1.5 x 10 9/L , platelet ≥ 100 x 10 9/L , hemoglobin ≥ 9 g/dL . Bilirubin ≥ 1.5 x ULN ASAT ALAT ≤ 2.5 x ULN ( ≤5 x ULN liver metastasis present ) Serum creatinine ≤ 1.5 x ULN Brain metastasis ( know suspect ) Previous chemotherapy metastatic disease . Prior adjuvant chemotherapy allow chemotherapy treatment free interval &gt; 6 month . Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior study entry Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Any investigational agent ( ) within 4 week prior entry Previous exposure EGFRpathway target therapy Clinically relevant coronary artery disease history myocardial infarction within last 12 month Acute subacute intestinal occlusion history inflammatory bowel disease Preexisting neuropathy &gt; grade 1 . In case prior oxaliplatin contain adjuvant chemotherapy : preexisting neuropathy ≥ 1 . Known grade 3 4 allergic reaction component treatment . Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Patients previous malignancy without evidence disease ≥ 5 year allow enter trial ) Pregnancy lactation Inadequate contraception ( male female patient ) childbearing procreational potential Known drug abuse/ alcohol abuse Legal incapacity limit legal capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>